Evidence map›Paper›PMID 40420296›Full record

ArticleAlzheimer's research & therapy2025

Protein co-aggregates of dense core amyloid plaques and CSF differ in rapidly progressive Alzheimer's disease and slower sporadic Alzheimer's disease.

Gurkan Bebek, Masaru Miyagi, Xinglong Wang, Brian S Appleby, James B Leverenz, Jagan A Pillai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gurkan BebekCenter for Proteomics and Bioinformatics, Department of Nutrition, Department of Computer and Data Sciences, Case Western Reserve University, Cleveland, 44106, OH, USA.
Masaru MiyagiDepartment of Pharmacology, Case Western Reserve University, Cleveland, 44106, OH, USA.
Xinglong WangDepartment of Pathology, University of Arizona, Tucson, 85721, AZ, USA.
Brian S ApplebyDepartment of Neurology, National Prion Disease Pathology Surveillance Center, University Hospitals Cleveland Medical Center, Cleveland, 44195, OH, USA.
James B LeverenzLou Ruvo Center for Brain Health, Neurological Institute, Department of Neurology, Cleveland, OH, USA.
Jagan A PillaiLou Ruvo Center for Brain Health, Neurological Institute, Department of Neurology, Cleveland, OH, USA. pillaij@ccf.org.

Funding

NIA NIH HHS 1P30 AG062428NIA NIH HHS P30 AG062428
6 · The paper itself

Abstract

backgroundThe rapidly progressive phenotype of Alzheimer's disease (rpAD) remains a rare and less-studied entity. Therefore, the replication of key results from the rpAD brain and cerebrospinal fluid (CSF) is lacking.

methodsA label-free quantitative LC-MS/MS analysis of proteins co-aggregating with core-amyloid

resultsA total of 1841 proteins were characterized in the FFT study, of which 463 were consistently identified in every rpAD patient analyzed. One thousand two hundred eighty-three proteins were shared between the FFT and the prior FFPE study. FFT offered a more comprehensive proteomic profile than the prior FFPE study and prominently included the immune system pathways. Thirty-five proteins were shared in the FFT brain tissue, matched CSF from the same subjects, in which biological processes related to immune response were again notable. These results were validated against prior published proteomic CSF AD data with a faster rate of progression to identify the top 5 potential protein biomarkers of rapid progression in AD CSF.

conclusionsThese results support a distinct immune-related proteomic profile in both the brain and the CSF that can be explored as potential biomarkers in the future for the clinical diagnosis of rpAD.

Indexed as

Alzheimer DiseasePlaque, AmyloidAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrainChromatography, LiquidDisease ProgressionFemaleHumansMaleMiddle AgedProteomicsTandem Mass SpectrometryAmyloid beta-PeptidesBiomarkersAlzheimer’s diseaseAutopsyCerebrospinal fluidCSFDementiaDense core amyloid plaqueFormalin-fixedFresh frozen tissueNeuroinflammationParaffin-embedded tissueProteomicsRapidly progressive Alzheimer’s diseaseRapidly progressive dementia

Identifiers

PMID40420296
PMCPMC12107742

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.